| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8963976 | Clinics and Research in Hepatology and Gastroenterology | 2018 | 6 Pages |
Abstract
The presence of anti-E1E2 at treatment initiation is a predictive factor of SVR among patients treated with DAA and more likely among patients with low initial HCV viral load (<Â 6log10). Absence of anti-E1E2 at baseline could predict DAA-treatment failure.
Keywords
DAAsimeprevirSOFSofosbuvirBOCpegylated-interferonTelaprevirSMVRBVPEG-IFNdcvSVRasunaprevirNeutralizing antibodiesDirect-acting antiviralBoceprevirELISAEnzyme-linked immunosorbent assaydirect-acting antiviralsdaclatasvirRibavirinrelapseTVRHepatitis CHCVHepatitis C virussustained virological responseGenotype
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Victor Virlogeux, Pascale Berthillon, Isabelle Bordes, Sylvie Larrat, Stéphanie Crouy, Caroline Scholtès, Pierre Pradat, Marianne Maynard, Fabien Zoulim, Vincent Leroy, Isabelle Chemin, Christian Trépo, Marie-Anne Petit,